Truist Financial Issues Pessimistic Forecast for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price target reduced by research analysts at Truist Financial from $50.00 to $46.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 45.99% from the stock’s current price.

A number of other research analysts also recently commented on the company. Bank of America lowered their target price on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Robert W. Baird lowered their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Stifel Nicolaus reduced their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Finally, Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Astrana Health presently has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Astrana Health Stock Performance

Shares of Astrana Health stock opened at $31.51 on Tuesday. The stock has a market cap of $1.77 billion, a PE ratio of 24.24, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. Astrana Health has a 12 month low of $23.12 and a 12 month high of $63.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The business has a fifty day simple moving average of $33.96 and a 200-day simple moving average of $42.76.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. On average, sell-side analysts anticipate that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

A number of hedge funds have recently bought and sold shares of the company. KBC Group NV bought a new stake in Astrana Health during the 3rd quarter valued at approximately $70,000. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Astrana Health during the fourth quarter worth approximately $40,000. Quarry LP bought a new stake in shares of Astrana Health in the third quarter valued at approximately $77,000. Quest Partners LLC acquired a new stake in shares of Astrana Health in the third quarter worth $133,000. Finally, Paloma Partners Management Co bought a new position in Astrana Health during the third quarter worth $220,000. 52.77% of the stock is currently owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.